RXII - RXIファ―マシュ―ティカルズ (RXi Pharmaceuticals Corporation)

RXIIのニュース

   RXI Pharmaceuticals Corporation (RXII) CEO Dr. Geert Cauwenbergh on Q3 2018 Results - Earnings Call Transcript  2018-11-14
RXI Pharmaceuticals Corporation (RXII) Q3 2018 Earnings Conference Call November 14, 2018 04:30 PM ET Executives Caitlin Kontulis - Senior Director of Finance Dr. Geert Cauwenbergh - CEO Dr. Gerrit Dispersyn - President and COO Analysts Anita Dushyanth - Zacks Small Capital…
   RXi Pharmaceuticals beats by $0.17, beats on revenue  2018-11-14
RXi Pharmaceuticals (NASDAQ: RXII ): Q3 GAAP EPS of -$0.34 beats by $0.17 . More news on: RXI Pharmaceuticals Corporation, Earnings news and commentary, Stocks on the move, Healthcare stocks news, , Read more …
   RXi Pharmaceuticals Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights  2018-11-14 PR Newswire
MARLBOROUGH, Mass. , Nov. 14, 2018 /PRNewswire/ --RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA) therapeutic platform, reports its f…

calendar